ReviewJournal of hematology & oncology2024

Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD-positive AML.

Jorge CortesPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.